tradingkey.logo

Rhythm Pharmaceuticals Inc

RYTM

89.040USD

+0.040+0.04%
Fechamento 07/10, 16:00ETCotações atrasadas em 15 min
5.65BValor de mercado
PerdaP/L TTM

Rhythm Pharmaceuticals Inc

89.040

+0.040+0.04%
Mais detalhes de Rhythm Pharmaceuticals Inc Empresa
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Informações da empresa
Código da empresaRYTM
Nome da EmpresaRhythm Pharmaceuticals Inc
Data de listagemOct 05, 2017
Fundado em2013
CEO- -
Número de funcionários283
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 05
Endereço222 Berkeley Street
CidadeBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02116
Telefone18572644280
Sitehttps://rhythmtx.com/
Código da empresaRYTM
Data de listagemOct 05, 2017
Fundado em2013
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
+6.36%
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
-0.35%
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
7.00K
+133.33%
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Independent Director
Independent Director
7.00K
+133.33%
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Alastair (Al) Garfield, Ph.D.
Dr. Alastair (Al) Garfield, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
+6.36%
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
-0.35%
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2023
FY2022
FY2021
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
96.11M
73.86%
International
34.02M
26.14%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
9.56%
PRIMECAP Management Company
9.10%
Baker Bros. Advisors LP
8.81%
BlackRock Institutional Trust Company, N.A.
6.29%
The Vanguard Group, Inc.
5.40%
Other
60.85%
Investidores
Investidores
Proporção
RA Capital Management, LP
9.56%
PRIMECAP Management Company
9.10%
Baker Bros. Advisors LP
8.81%
BlackRock Institutional Trust Company, N.A.
6.29%
The Vanguard Group, Inc.
5.40%
Other
60.85%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
33.95%
Investment Advisor
29.07%
Venture Capital
15.18%
Hedge Fund
14.38%
Private Equity
5.67%
Research Firm
3.79%
Individual Investor
0.70%
Bank and Trust
0.70%
Sovereign Wealth Fund
0.32%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
446
66.23M
104.10%
-6.62M
2025Q1
464
66.24M
104.13%
-6.91M
2024Q4
438
66.17M
104.69%
-7.75M
2024Q3
414
68.98M
112.28%
-7.86M
2024Q2
402
70.62M
115.59%
-5.66M
2024Q1
385
68.75M
112.78%
-8.84M
2023Q4
369
67.33M
113.30%
-8.52M
2023Q3
350
68.72M
116.31%
-2.96M
2023Q2
327
67.69M
118.97%
+564.21K
2023Q1
340
61.98M
109.09%
-8.65M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
6.08M
9.56%
--
--
Mar 31, 2025
PRIMECAP Management Company
5.79M
9.1%
-783.87K
-11.93%
Mar 31, 2025
Baker Bros. Advisors LP
5.60M
8.81%
-479.77K
-7.89%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.00M
6.29%
-64.82K
-1.59%
Mar 31, 2025
The Vanguard Group, Inc.
3.43M
5.4%
+2.33K
+0.07%
Mar 31, 2025
New Enterprise Associates (NEA)
2.91M
4.57%
--
--
Mar 31, 2025
Perceptive Advisors LLC
2.55M
4.01%
-1.13M
-30.76%
Mar 31, 2025
State Street Global Advisors (US)
1.97M
3.1%
+129.86K
+7.05%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.69M
2.66%
-26.51K
-1.54%
Mar 31, 2025
Janus Henderson Investors
1.66M
2.6%
+435.80K
+35.73%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
ALPS Medical Breakthroughs ETF
3.41%
Virtus LifeSci Biotech Products ETF
1.99%
Innovator IBD 50 Fund ETF
1.93%
Harbor Health Care ETF
1.69%
Harbor Human Capital Factor US Small Cap ETF
1.42%
iShares Health Innovation Active ETF
1.19%
SPDR S&P Biotech ETF
0.86%
Federated Hermes MDT Small Cap Core ETF
0.7%
NYLI Healthy Hearts ETF
0.61%
First Trust Small Cap Growth AlphaDEX Fund
0.56%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção3.41%
Virtus LifeSci Biotech Products ETF
Proporção1.99%
Innovator IBD 50 Fund ETF
Proporção1.93%
Harbor Health Care ETF
Proporção1.69%
Harbor Human Capital Factor US Small Cap ETF
Proporção1.42%
iShares Health Innovation Active ETF
Proporção1.19%
SPDR S&P Biotech ETF
Proporção0.86%
Federated Hermes MDT Small Cap Core ETF
Proporção0.7%
NYLI Healthy Hearts ETF
Proporção0.61%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.56%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI